Nothing Special   »   [go: up one dir, main page]

UY37971A - Derivados de indol macrocíclicos sustituidos - Google Patents

Derivados de indol macrocíclicos sustituidos

Info

Publication number
UY37971A
UY37971A UY0001037971A UY37971A UY37971A UY 37971 A UY37971 A UY 37971A UY 0001037971 A UY0001037971 A UY 0001037971A UY 37971 A UY37971 A UY 37971A UY 37971 A UY37971 A UY 37971A
Authority
UY
Uruguay
Prior art keywords
compounds
deritates
indol
preparation
substituted macrocyclic
Prior art date
Application number
UY0001037971A
Other languages
English (en)
Inventor
Philipp Buchgraber Dr
Kai Thede Dr
Anne Mengel Dr
Clara Christ Dr
Joachim Kuhnke Dr
Sarah Anna Liesa Johannes Dr
Ulrich Klar Dr
Ulrike Sack Dr
Stefan Kaulfuss Dr
Nicolas Werbeck Dr
Ursula Mönning Dr
Katrin Nowak-Reppel Dr
Sven Wittrock Dr
David Mckinney
Chris Lemke
Mark Fitzgerald
Christopher Nasveschuk
Kiel Lazarski
James Ferrara Steven
Laura Furst
Ryan Mccarren Patrick
Ann Harvey Rebecca
Guo Wei
H Serrano-Wu Michael
Amaury Ernesto Fernandez-Montalvan Dr
Original Assignee
Bayer Ag
Broad Inst Inc
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Broad Inst Inc, Bayer Pharma AG filed Critical Bayer Ag
Publication of UY37971A publication Critical patent/UY37971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a derivados de indol macrocíclicos sustituidos de la fórmula general (I) en la cual R1, R2, R3, R4, R5, R6, A y L son como se definen en el presente, a procedimientos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular de trastornos hiperproliferativos, como un único agente o en combinación con otros ingredientes activos.
UY0001037971A 2017-11-17 2018-11-15 Derivados de indol macrocíclicos sustituidos UY37971A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587935P 2017-11-17 2017-11-17

Publications (1)

Publication Number Publication Date
UY37971A true UY37971A (es) 2019-06-28

Family

ID=64556851

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037971A UY37971A (es) 2017-11-17 2018-11-15 Derivados de indol macrocíclicos sustituidos

Country Status (9)

Country Link
US (2) US11440923B2 (es)
EP (1) EP3710451A1 (es)
JP (1) JP7234250B2 (es)
CN (1) CN111757884B (es)
AR (1) AR113888A1 (es)
CA (1) CA3082735A1 (es)
TW (1) TWI810220B (es)
UY (1) UY37971A (es)
WO (1) WO2019096922A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458459B1 (en) 2016-05-19 2022-04-27 Bayer Aktiengesellschaft Macrocyclic indole derivatives
US11286263B2 (en) 2017-11-17 2022-03-29 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives
EP3710450A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
AR113886A1 (es) 2017-11-17 2020-06-24 Broad Inst Inc Derivados de indol macrocíclicos
AR113887A1 (es) 2017-11-17 2020-06-24 Bayer Ag Derivados de indol macrocíclicos sustituidos con cloro
AR113888A1 (es) 2017-11-17 2020-06-24 Bayer Ag Derivados de indol macrocíclicos sustituidos
EP3969457A4 (en) * 2019-05-17 2023-05-24 The Broad Institute Inc. PROCESS FOR THE PRODUCTION OF MACROCYCLIC INDOLES
WO2024083223A1 (zh) * 2022-10-21 2024-04-25 正大天晴药业集团股份有限公司 大环类化合物及其医药用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101615B2 (en) 2004-02-26 2012-01-24 Bayer Pharma Aktiengesellschaft 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
MX2009011211A (es) 2007-04-16 2009-10-30 Abbott Lab Indoles sustituidos en la posicion 7 inhibidores de mci-1.
WO2008130970A1 (en) 2007-04-16 2008-10-30 Abbott Laboratories 7-nonsubstituted indole mcl-1 inhibitors
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10093640B2 (en) * 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
WO2015031608A1 (en) 2013-08-28 2015-03-05 Vanderbilt University Substituted indole mcl-1 inhibitors
EP3122353B1 (en) 2014-03-27 2020-10-28 Vanderbilt University Substituted indole mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
EA038143B1 (ru) 2016-03-04 2021-07-13 Вандербилт Юниверсити ИНГИБИТОРЫ Mcl-1 НА ОСНОВЕ ЗАМЕЩЕННЫХ ИНДОЛОВ
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
TN2018000319A1 (en) 2016-04-22 2020-01-16 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
EP3458459B1 (en) 2016-05-19 2022-04-27 Bayer Aktiengesellschaft Macrocyclic indole derivatives
WO2018098534A1 (en) 2016-12-02 2018-06-07 Garvan Institute Of Medical Research Methods of treating cancer and reagents thereof
US11286263B2 (en) 2017-11-17 2022-03-29 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives
AR113886A1 (es) 2017-11-17 2020-06-24 Broad Inst Inc Derivados de indol macrocíclicos
WO2019096907A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
AR113887A1 (es) 2017-11-17 2020-06-24 Bayer Ag Derivados de indol macrocíclicos sustituidos con cloro
EP3710450A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
AR113888A1 (es) 2017-11-17 2020-06-24 Bayer Ag Derivados de indol macrocíclicos sustituidos
EP3781575A4 (en) 2019-01-23 2021-06-02 Ascentage Pharma (Suzhou) Co., Ltd. MACROCYCLIC FUSION PYRRAZOLES USED AS MCL-1 INHIBITORS
EP3969457A4 (en) 2019-05-17 2023-05-24 The Broad Institute Inc. PROCESS FOR THE PRODUCTION OF MACROCYCLIC INDOLES

Also Published As

Publication number Publication date
US11891404B2 (en) 2024-02-06
TWI810220B (zh) 2023-08-01
EP3710451A1 (en) 2020-09-23
AR113888A1 (es) 2020-06-24
WO2019096922A1 (en) 2019-05-23
US20230112244A1 (en) 2023-04-13
US20210269456A1 (en) 2021-09-02
JP7234250B2 (ja) 2023-03-07
CA3082735A1 (en) 2019-05-23
US11440923B2 (en) 2022-09-13
TW201936185A (zh) 2019-09-16
CN111757884B (zh) 2023-12-19
CN111757884A (zh) 2020-10-09
JP2021503508A (ja) 2021-02-12

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
UY37971A (es) Derivados de indol macrocíclicos sustituidos
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CO2019014484A2 (es) Nuevos derivados de azaquinolina
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
UY37250A (es) Derivados macrocíclicos de indol
UY37832A (es) Dihidrooxadiazinonas
UY37705A (es) Nuevos derivados de pirazol bicíclicos
UY37973A (es) Derivados de indol macrocíclicos
CO2020013876A2 (es) Nuevos derivados de quinolina
UY38816A (es) Nuevos derivados de isoquinolina
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
UY37032A (es) Compuestos de heteroarilbenzimidazol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114